Company or ticker...

Enliven Therapeutics

Enliven develops small molecule cancer drugs focused on genetically defined tumors.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

ELVN

3.5B

0.0

n/a

223.10%

Key Facts

M. Cap

PS

PE

YTD

3.5B

0.0

n/a

223.10%

10MA

20MA

50MA

200MA

$ELVN